Thermo Fisher Scientific Inc
TMO: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$421.00 | Vhdzs | Ymgvyzbvxr |
Thermo Fisher Scientific Sees Strong Performance in Q1 as Vaccines Contribute to COVID-19 Windfall
We are maintaining our fair value estimate for wide-moat Thermo Fisher Scientific following the release of first-quarter results. The company delivered strong performance, with healthy recovery in the base business (up 13% organically), supported by $2.9 billion in COVID-19 pandemic response revenue. The shares appear fairly valued at current levels.